Repertoire® Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell-targeted immune medicines, today announced that the first participant has been ...
Scientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3’s advancement ...
Researchers at the University of British Columbia Faculty of Medicine have developed a new targeted cancer therapy that can ...
A KAIST research team has identified the real reason why anticancer drugs kill cancer cells—targeted anticancer therapies do ...
The ATOMIC Trial shows how adding immunotherapy to chemotherapy may reduce recurrence risk and improve outcomes in stage III ...
OPKO Health subsidiary ModeX Therapeutics has started dosing patients with its tetraspecific T-cell engager, MDX2003, for ...
Explore how BTK resistance drives poor outcomes in relapsed mantle cell lymphoma and why ZUMA-2 CAR T therapy emerges as a ...
As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions. The European Medicines Agency’s ...
Off-the-shelf cema-cel clears MRD at more than triple the rate of observation alone—and may propel a shift to frontline use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results